click enter text
initi peer perform
summari invest thesi essenti move sidelin
peer perform rate first becam construct
stock back heavili favor tide
turn consensu buy deliv varieti way
margin expans pipelin deliveri pend capit market event
wherebi divest anim health divis long-term outlook
bright flip side expect quit high lli valuat
risen dramat next year face least headwind
like ciali go gener spend step may tamp
earn growth out-performance near-term seem
unlik thu move sidelin fundament
concern primarili valuat great run
exhibit show incom statement revenu balanc sheet
initi report price octob
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak tanezumab anti-ngf pain galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
